Our Work

MME serves as a leading voice in the global PRMA space. MME frequently presents thought leadership and research at society meetings such as ISPOR as well as industry events. MME is also proud to share the positive outcomes they’ve helped clients achieve across a range of challenges at different points in the life-cycle, regions and competitive scenarios. Read about just a few ways MME has helped guide the industry in how to build and sustain value.

Case Studies

Pricing Strategy Assessment for Product Launch

May 12, 2020

We conducted a pricing strategy assessment for a mid-sized international pharmaceutical company in the process of developing a new product in a specialty therapeutic area. The project included interviews with 25 pharmacy directors and 25 physicians, covering 209 million lives in the United States and ten payers in the EU5.

MULTI-COUNTRY PAYER QUALITATIVE RESEARCH

May 11, 2020

We worked with a US-based biopharmaceutical company with a solid oral product in an established, competitive disease state to gain payer insights into drug pricing and optimize PRMA in multiple countries.

Segmentation, Contracting, Gross to Net and Understanding Payers

May 7, 2020

A small to mid-sized US pharmaceutical manufacturer preparing to launch a new product hired us to maximize their positioning within a competitive market landscape. The project objectives were wide-ranging, consisting of segmenting payers to understand volume and access contribution, prioritizing MCO accounts, and selectively contracting to improve access and utilization management (UM).

Competitive Engagement Simulation®

May 7, 2020

We worked with a mid-sized pharmaceutical manufacturer based in the US preparing to launch a product in a competitive market. The client hired us to evaluate four to six possible marketplace scenarios to determine possible appropriate actions under certain marketplace conditions.

A 10-year review (2009-2018) of market access of pharmaceuticals in the EU5 and US.

December 1, 2019

Market access trends across the EU5 and US: 2009 to 2018 – an update.

June 1, 2019

EU5 market access for medicines approved under exceptional circumstances.

December 1, 2018

Market access trends for advanced therapy medicinal products (ATMPs) in Europe.